Login to Your Account



Pharma: Clinic Roundup


Wednesday, July 17, 2013
• Baxter International Inc., of Deerfield, Ill., presented data at the Alzheimer's Association International Conference in Boston from the Phase III Gammaglobulin Alzheimer's Partnership study showing that, as previously disclosed, the study did not meet its co-primary endpoints of reducing cognitive decline and preserving functional abilities in patients with mild to moderate Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription